slides

Evaluation of Everolimus (EVE) in HER2+ advanced breast cancer (BC) with activated PI3K/mTOR pathway : exploratory biomarker observations from the BOLERO-3 trial

Authors
Publication date
1 September 2013
Publisher
Elsevier Science

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Open Repository and Bibliography - Liège

    redirect
    oaioai:orbi.ulg.ac.be:2268/156818
    Last time updated on 10/10/2013